April 4, 2014
SHINE Medical Technologies, Inc. (SHINE) announced that it has entered into a strategic long‐term supply agreement with GE Healthcare, a division of the General Electric Company, for supply of molybdenum‐99 (moly‐99). Moly‐99 decays into the diagnostic imaging agent technetium‐99m (Tc‐99m). Tc‐99m’s is the most commonly‐used medical isotope and is used in over 40 million medical imaging procedures per year. Under the terms of the supply agreement, SHINE will provide moly‐99 to GE Healthcare on a regular basis once its facility becomes operational.
The full SHINE Press Release can be found here.